Events & Presentations Events & Presentations Latest Corporate Presentation October 4, 2021 Checkmate Pharmaceuticals Corporate Overview – October 2021 Upcoming Events Jefferies KOL Webinar: Innate Immunity and Vidutolimod (CMP-001) Oct 26, 2021 at 11:00 AM EDT Click here for webcast Supporting Materials View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod 11.8 MB Past Events Cantor Virtual Global Healthcare Conference Sep 30, 2021 at 10:40 AM EDT Click here for webcast H.C. Wainwright 23rd Annual Global Investment Conference Sep 13, 2021 at 7:00 AM EDT BTIG Virtual Biotechnology Conference Aug 9, 2021 at 3:30 PM EDT Presentations SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a… SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra… Oct 26, 2021 View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod 11.8 MB SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (… AACR 2019. Miller, Ann, et al. Source 79(13 Suppl): Abstract 3273. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatmen… ASCO 2018. Massa, Ryan, et al. Source 36(15 Suppl): e21507. Relationship between pre-treatment organ-specific tumor burden (TB) and respons… AACR 2018. Milhem, Mohammed, et al. Source 78(13 Suppl): Abstract CT144. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with … AACR 2017. Bichat, Francis, et al. Source 77(13 Suppl): Abstract 2669. Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modu… ASH 2016. Lemke, Caitlin, et al. Source Blood 128(22): Abstract 3023. Combination lymphoma immunotherapy using checkpoint blockade and intratumoral v… ASCO 2016. Milhem, Mohammed, et al. Source J Clin Oncol 34: Abstract TPS9593. Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab… Pagination First page « first Previous page ‹ previous Page 1 Current page 2
Events & Presentations Latest Corporate Presentation October 4, 2021 Checkmate Pharmaceuticals Corporate Overview – October 2021 Upcoming Events Jefferies KOL Webinar: Innate Immunity and Vidutolimod (CMP-001) Oct 26, 2021 at 11:00 AM EDT Click here for webcast Supporting Materials View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod 11.8 MB Past Events Cantor Virtual Global Healthcare Conference Sep 30, 2021 at 10:40 AM EDT Click here for webcast H.C. Wainwright 23rd Annual Global Investment Conference Sep 13, 2021 at 7:00 AM EDT BTIG Virtual Biotechnology Conference Aug 9, 2021 at 3:30 PM EDT Presentations SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a… SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra… Oct 26, 2021 View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod 11.8 MB SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (… AACR 2019. Miller, Ann, et al. Source 79(13 Suppl): Abstract 3273. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatmen… ASCO 2018. Massa, Ryan, et al. Source 36(15 Suppl): e21507. Relationship between pre-treatment organ-specific tumor burden (TB) and respons… AACR 2018. Milhem, Mohammed, et al. Source 78(13 Suppl): Abstract CT144. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with … AACR 2017. Bichat, Francis, et al. Source 77(13 Suppl): Abstract 2669. Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modu… ASH 2016. Lemke, Caitlin, et al. Source Blood 128(22): Abstract 3023. Combination lymphoma immunotherapy using checkpoint blockade and intratumoral v… ASCO 2016. Milhem, Mohammed, et al. Source J Clin Oncol 34: Abstract TPS9593. Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab… Pagination First page « first Previous page ‹ previous Page 1 Current page 2
Jefferies KOL Webinar: Innate Immunity and Vidutolimod (CMP-001) Oct 26, 2021 at 11:00 AM EDT Click here for webcast Supporting Materials View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod 11.8 MB
View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod 11.8 MB
SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a…
Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a…
SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra…
Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra…
Oct 26, 2021 View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod 11.8 MB
View slides: Overcoming challenges in innate immune activation: the unique effects of vidutolimod 11.8 MB
SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (…
Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (…
AACR 2019. Miller, Ann, et al. Source 79(13 Suppl): Abstract 3273. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatmen…
ASCO 2018. Massa, Ryan, et al. Source 36(15 Suppl): e21507. Relationship between pre-treatment organ-specific tumor burden (TB) and respons…
AACR 2018. Milhem, Mohammed, et al. Source 78(13 Suppl): Abstract CT144. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with …
AACR 2017. Bichat, Francis, et al. Source 77(13 Suppl): Abstract 2669. Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modu…
ASH 2016. Lemke, Caitlin, et al. Source Blood 128(22): Abstract 3023. Combination lymphoma immunotherapy using checkpoint blockade and intratumoral v…
ASCO 2016. Milhem, Mohammed, et al. Source J Clin Oncol 34: Abstract TPS9593. Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab…
